← Leaderboards
Susumu Kobayashi
Beth Israel Deaconess Medical Center
$5,296,351
Attributed
$5,296,351
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $594.7K · FY2007–24$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,296,351 · 5
By mechanism
R01$3,773,013 · 2
R00$824,671 · 1
R21$434,607 · 1
K99$264,060 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Daniel Botelho Costa$3,158,732
- Kathryn Elaine Stephenson$9,687,291
- Daniel G Tenen$44,879,800
- Ramy Arnaout$3,713,857
- Alexander Banks$8,101,531
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationTumorMalignant Neoplasm Of LungNovel TherapeuticsNovel StrategiesMutantResistanceTyrosine Kinase InhibitorFutureEpidermal Growth Factor ReceptorLeadCancer EtiologyPathway InteractionsChemotherapyGefitinibInsightErlotinibResponseMalignant NeoplasmsOncogenicCancer TherapyIn VivoCellsMouse Model
Grant awards (19)
Role of KAT5 in lung cancer$379,196
R01 · FY2024 · CA · contact PI
Role of KAT5 in lung cancer$391,170
R01 · FY2023 · CA · contact PI
Role of KAT5 in lung cancer$391,170
R01 · FY2022 · CA · contact PI
Role of KAT5 in lung cancer$399,154
R01 · FY2021 · CA · contact PI
Role of KAT5 in lung cancer$417,904
R01 · FY2020 · CA · contact PI
Overcoming resistance to tyrosine kinase inhibitors in lung cancer$361,049
R01 · FY2018 · CA · contact PI
Overcoming resistance to tyrosine kinase inhibitors in lung cancer$1
R01 · FY2017 · CA · contact PI
Overcoming resistance to tyrosine kinase inhibitors in lung cancer$361,050
R01 · FY2016 · CA · contact PI
Emergence of drug resistant mutations in lung cancer$233,611
R21 · FY2016 · CA · contact PI
Overcoming resistance to tyrosine kinase inhibitors in lung cancer$361,050
R01 · FY2015 · CA · contact PI
Emergence of drug resistant mutations in lung cancer$200,996
R21 · FY2015 · CA · contact PI
Overcoming resistance to tyrosine kinase inhibitors in lung cancer$350,219
R01 · FY2014 · CA · contact PI
Overcoming resistance to tyrosine kinase inhibitors in lung cancer$361,050
R01 · FY2013 · CA · contact PI
Role of EGFR mutations and new therapeutics in lung cancer$241,530
R00 · FY2011 · CA · contact PI
Role of EGFR mutations and new therapeutics in lung cancer$249,000
R00 · FY2010 · CA · contact PI
Role of EGFR mutations and new therapeutics in lung cancer$249,000
R00 · FY2009 · CA · contact PI
Role of EGFR mutations and new therapeutics in lung cancer$85,141
R00 · FY2009 · CA · contact PI
Role of EGFR mutations and new therapeutics in lung cancer$132,030
K99 · FY2008 · CA · contact PI
Role of EGFR mutations and new therapeutics in lung cancer$132,030
K99 · FY2007 · CA · contact PI